# Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

> **NCT04155541** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 40 (actual)

## Conditions studied

- EGFR Mutation-positive Inoperable or Reccrent NSCLC

## Interventions

- **DRUG:** dacomitinib hydrate

## Key facts

- **NCT ID:** NCT04155541
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-24
- **Primary completion:** 2025-04-25
- **Final completion:** 2025-04-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04155541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04155541, "Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04155541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*